News

Patient 6: Cancer-free at six months

Following the success of Patient 5, Patient 6 has now also demonstrated no recurrence of bladder cancer at the 180 day clinical…

Patient 5: Cancer-free at six months

Patient 5 tolerated the single-dose treatment well, and has demonstrated no tumor recurrence or presence of disease at the 180 day clinical…

Phase Ib trial successfully completed

Based on the encouraging results of the first patients in the trial, the Medical and Scientific Advisory Board (“MSAB”) unanimously recommended the…

AGM videos online

Theralase has released three videos that were presented at its annual meeting. They cover the successful completion of the Phase Ib trial,…

More great news from the clinical trial

Very encouraging news from the clinic! Patient Five shows no clinical evidence or presence of NMIBC (non muscle invasive bladder cancer) at…

Sixth patient treated

A sixth patient — the third to receive the full therapeutic dose — has been treated. The primary, secondary, and exploratory endpoints…

Fifth patient treated for cancer

A fifth patient has been treated for non-muscle invasive bladder cancer with our drug TLD-1433. Consult the press release for more information.

Interim analysis of trial data: exploratory outcomes met

The interim analysis of the trial data has yielded promising results. A high level of safety, tolerability, and pharmacokinetics was demonstrated in…

A fourth patient has been successfully treated with TLD1433. Your days are numbered, bladder cancer!

Continuing the Phase Ib clinical trial, a fourth patient has now been successfully treated with our PDT technology for non-muscle invasive bladder…

Our compound TLD1433 has entered a human clinical trial! UPDATE: 3 patients treated! Six more to be enrolled in the study.

Our compound TLD1433 is in a clinical trial for non-muscle invasive bladder cancer! The primary and secondary objectives for the first three…